机构:[1]Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.[2]Institute of Materials Science & Engineering, EPFL, Lausanne, Switzerland.[3]Department of Oncology, University of Lausanne, Epalinges, Switzerland.[4]Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.[5]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.四川大学华西医院[6]Center for Genomics and Systems Biology, New York University Abu Dhabi, Abu Dhabi, United Arab[7]Siriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.[8]Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[9]Department of Oncology of the First Affiliated Hospital, Division of Life Sciences and Medicine, The CAS Key Laboratory of Innate Immunity and Chronic Disease, Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei, China.
T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among exhausted CD8+ tumor-infiltrating lymphocytes, the terminally exhausted subset contributes directly to tumor cell killing owing to its cytotoxic effector function. However, this subset does not respond to immune checkpoint blockades and is difficult to be reinvigorated with restored proliferative capacity. Here, we show that a half-life-extended interleukin-10-Fc fusion protein directly and potently enhanced expansion and effector function of terminally exhausted CD8+ tumor-infiltrating lymphocytes by promoting oxidative phosphorylation, a process that was independent of the progenitor exhausted T cells. Interleukin-10-Fc was a safe and highly efficient metabolic intervention that synergized with adoptive T cell transfer immunotherapy, leading to eradication of established solid tumors and durable cures in the majority of treated mice. These findings show that metabolic reprogramming by upregulating mitochondrial pyruvate carrier-dependent oxidative phosphorylation can revitalize terminally exhausted T cells and enhance the response to cancer immunotherapy.
基金:
This work was supported in
part by the Swiss National Science Foundation (SNSF project grant no. 315230_173243),
the ISREC Foundation with a donation from the Biltema Foundation, the Swiss Cancer
League (grant no. KFS-4600-08-2018), the European Research Council under the
ERC grant agreement MechanoIMM (grant no. 805337), the Kristian Gerhard Jebsen
Foundation, Fondation Pierre Mercier pour la science, an Anna Fuller Fund grant and
the EPFL (L.T.). P.-C.H. was supported in part by the Swiss Institute for Experimental
Cancer Research (ISREC grant no. 26075483), SNSF project grants (grant nos.
31003A_163204 and 31003A_182470), the Cancer Research Institute Lloyd J. Old STAR
award and the European Research Council Starting Grant (grant no. 802773-MitoGuide).
P.R. was supported in part by grants from the SNSF (grant nos. 310030_182735 and 310030E-164187). W.H. was supported in part by the Swiss Cancer League (grant no.
KFS-4407-02-2018) and the SNSF (grant no. 310030B_179570). W.X. was supported
in part by the Strategic Priority Research Program of the Chinese Academy of Sciences
(grant no. XDB29030000) and the Ministry of Science and Technology of China (grant
no. 2016YFC1303503). M.G. was supported by the Chinese Scholarship Council (grant
no. 201808320453).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|1 区医学
小类|1 区免疫学
最新[2023]版:
大类|1 区医学
小类|1 区免疫学
第一作者:
第一作者机构:[1]Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.[2]Institute of Materials Science & Engineering, EPFL, Lausanne, Switzerland.
共同第一作者:
通讯作者:
通讯机构:[1]Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.[2]Institute of Materials Science & Engineering, EPFL, Lausanne, Switzerland.[3]Department of Oncology, University of Lausanne, Epalinges, Switzerland.[4]Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
推荐引用方式(GB/T 7714):
Guo Yugang,Xie Yu-Qing,Gao Min,et al.Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity.[J].Nature immunology.2021,22(6):746-756.doi:10.1038/s41590-021-00940-2.
APA:
Guo Yugang,Xie Yu-Qing,Gao Min,Zhao Yang,Franco Fabien...&Tang Li.(2021).Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity..Nature immunology,22,(6)
MLA:
Guo Yugang,et al."Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity.".Nature immunology 22..6(2021):746-756